快盈500

3SBio Group has always been committed to solving the problem of
clinical drug use for patients, constantly conquering the challenges
of the disease, using high-quality drugs to improve the quality of
快盈500 life of patients, and working hard for the benefit of human health.

Cooperation partners

  • Exclusive license for the commercialization of GLP-1 products in China

  • Exclusive license to develop and commercialize programmed therapeutic cells in Greater China

  • Exclusive license for the distribution and promotion of insulin products

  • Collaboration for clinical development and commercialization of MCM1 in China

  • Exclusive partnership to commercialize liposomal products utilizing NanoX™ in Mainland China


  • 快盈500Priority for potential licensing or development of two ophthalmic-related disease products

  • Exclusive right to develop and commercialize Remitch in China

  • 快盈500Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology

  • Collaboration for clinical development and commercialization of multiple biosimilars in China

  • Potential licensing priorities for four inner ear disease related research products

  • 快盈500Investment to research and develop early stage cancer drugs

天美糖心果冻麻花-天美糖心果冻乌鸦糖心-天美果冻91-天美星空果冻mv视频-天美麻花星空mv视频 百万至尊 - 欢迎您 800cc彩票 - 首页 10218旭彩网 五六三十彩票 - 首页 顺泰国际 - 首页 鸿发国际 - 安全购彩 纵横联盟(中国区)集团官方网站